

R126
34 ~~13~~. (New) An isolated infectious respiratory syncytial virus particle which comprises a respiratory syncytial virus antigenome or genome containing at least one L gene mutation, wherein said L gene mutation encodes an amino acid exchange from a charged amino acid to an alanine.

Sub. D3
37 ~~14~~. (New) The isolated infectious respiratory syncytial virus particle of claim ~~13~~ ³⁶, wherein said mutation is selected from a group consisting of A33, A73, A171, A81, A185, A91, A101, A192, A11, A111, A121, A133, A141, A25, A45, A153, A162, A201, A211, A221, A231, A241, A57, A65, A251, A261, AD11, AD21, AD31, F1, and F13.

38 ~~15~~. (New) An isolated infectious respiratory syncytial virus particle which comprises a respiratory syncytial virus antigenome or genome containing at least one L gene mutation, wherein said L gene mutation encodes an amino acid exchange from a cysteine to an amino acid selected from a group comprising glycine, valine, aspartic acid, and alanine.

Sub. D4
39 ~~16~~. (New) The isolated infectious respiratory syncytial virus particle of claim ~~15~~ ³⁸, wherein said cysteine is selected from a group consisting of cysteine at amino acid position 781, 924, 1183, 1347, and 1604.

Sub. D5
40 ~~17~~. (New) An isolated infectious respiratory syncytial virus particle which comprises a respiratory syncytial virus antigenome or genome containing at least one M2-1 gene mutation, wherein said M2-1 gene mutation encodes an amino acid exchange from a cysteine to an amino acid selected from a group comprising glycine, valine, aspartic acid, and alanine.

41 ~~18~~. (New) The isolated infectious respiratory syncytial virus particle of claim ~~17~~ ⁴⁰, wherein said cysteine is selected from a group consisting of cysteine at amino acid position 7, 15, 21, and 96.

RRP 42 19. (New) An isolated infectious respiratory syncytial virus particle which comprises a respiratory syncytial virus antigenome or genome containing a C-terminal truncation of the M2-1 protein.

Sub.D 43 20. (New) The isolated infectious respiratory syncytial virus particle of claim 19, wherein the stop codon causing said C-terminal truncation is at a position selected from a group consisting of nucleotide position 7987-7989, 7990-7993, 8050-8052, 8053-8055, 8137-8139, or 8140-8142. 42

SUBSTITUTE SPECIFICATION

The enclosed rewritten specification is being provided by Applicants as a substitute specification pursuant to 37 C.F.R. § 1.125(b) and M.P.E.P. § 608.01(q). The specification has been amended to incorporate sequence identifiers as well as listing of all figures labeled with letter designations. Also, minor typographical errors such as the application number for one of the priority documents and the designation of the 5' end of the reverse strand of the oligonucleotide designated as SEQ ID NO:32 have been corrected. Accordingly, pursuant to 37 C.F.R. § 1.125(b)(1), Applicants' representatives hereby state that the enclosed substitute specification includes no new matter. Pursuant to 37 C.F.R. § 1.125(b)(2), a "marked-up" copy of the substitute specification showing the matter being added to (bold, double underlined) and the matter being deleted from (struck through) the specification of record (*i.e.* Application No. 09/368,076 filed August 3, 1999).

M.P.E.P. § 608.01(q) provides Office guidance and procedures relating to substitute or rewritten specifications:

A substitute specification filed under 37 CFR 1.125(b) must be accompanied by a statement indicating that no new matter was included. There is no obligation on the examiner to make a detailed comparison between the old and the new specifications for determining